Partners PrEP Study
Generated by Llama 3.3-70BExpansion Funnel Raw 53 → Dedup 0 → NER 0 → Enqueued 0
| Partners PrEP Study | |
|---|---|
| Name | Partners PrEP Study |
| Funding | Bill and Melinda Gates Foundation, National Institutes of Health |
| Date | 2008-2011 |
| Location | Kenya, Uganda |
| Participants | 4758 |
Partners PrEP Study was a landmark clinical trial conducted by University of Washington researchers, including Jared Baeten and Connie Celum, in collaboration with the Kenya Medical Research Institute and the Uganda Virus Research Institute. The study aimed to investigate the efficacy of antiretroviral therapy (ART) as a preventive measure against HIV transmission among serodiscordant couples, where one partner is HIV-positive and the other is HIV-negative. The trial was funded by the Bill and Melinda Gates Foundation and the National Institutes of Health, with support from the World Health Organization and the Joint United Nations Programme on HIV/AIDS.
Introduction
The Partners PrEP Study was designed to address the high rates of HIV transmission among serodiscordant couples in sub-Saharan Africa, where HIV/AIDS is a major public health concern. The study built upon earlier research by Myron Cohen and Quarraisha Abdool Karim, which demonstrated the effectiveness of antiretroviral therapy in reducing HIV transmission. The Partners PrEP Study involved a large cohort of serodiscordant couples from Kenya and Uganda, with participants receiving either emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) or a placebo. The study was conducted in collaboration with the Kenya Medical Research Institute and the Uganda Virus Research Institute, with support from the Centers for Disease Control and Prevention and the World Health Organization.
Background
The Partners PrEP Study was informed by earlier research on HIV prevention and antiretroviral therapy, including the iPrEx study and the TDF2 study. These studies demonstrated the efficacy of pre-exposure prophylaxis (PrEP) in reducing HIV transmission among high-risk populations, including men who have sex with men and heterosexual couples. The Partners PrEP Study built upon this research, investigating the effectiveness of PrEP in a real-world setting among serodiscordant couples in sub-Saharan Africa. The study was also influenced by the work of Anthony Fauci and the National Institute of Allergy and Infectious Diseases, which has played a critical role in advancing HIV research and global health initiatives.
Methodology
The Partners PrEP Study employed a randomized, double-blind, placebo-controlled design, with participants receiving either emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) or a placebo. The study involved a large cohort of 4758 serodiscordant couples from Kenya and Uganda, with participants followed for up to 24 months. The study was conducted in collaboration with the Kenya Medical Research Institute and the Uganda Virus Research Institute, with support from the Centers for Disease Control and Prevention and the World Health Organization. The study's methodology was informed by the work of Stephen Hawkes and the London School of Hygiene & Tropical Medicine, which has made significant contributions to global health research and epidemiology.
Results
The Partners PrEP Study demonstrated a significant reduction in HIV transmission among serodiscordant couples receiving emtricitabine/tenofovir disoproxil fumarate (TDF/FTC). The study found that PrEP reduced HIV transmission by 75% among participants, with the highest efficacy observed among those with high adherence to the medication regimen. The study's results were published in the New England Journal of Medicine and presented at the International AIDS Conference, with implications for HIV prevention and global health policy. The study's findings were also influenced by the work of Michel Kazatchkine and the Global Fund to Fight AIDS, Tuberculosis and Malaria, which has played a critical role in advancing HIV prevention and treatment initiatives.
Impact
The Partners PrEP Study has had a significant impact on HIV prevention and global health policy, with implications for the use of pre-exposure prophylaxis (PrEP) in high-risk populations. The study's findings have informed the development of WHO guidelines on PrEP, with recommendations for its use in serodiscordant couples and other high-risk populations. The study's results have also been cited by the US Centers for Disease Control and Prevention and the European Centre for Disease Prevention and Control, with implications for HIV prevention and public health policy. The study's impact has been recognized by UNAIDS and the Bill and Melinda Gates Foundation, which have highlighted the importance of PrEP in reducing HIV transmission and advancing global health goals.
Conclusion
The Partners PrEP Study has made a significant contribution to our understanding of HIV prevention and the effectiveness of pre-exposure prophylaxis (PrEP) in reducing HIV transmission. The study's findings have implications for global health policy and the development of HIV prevention strategies, with a focus on serodiscordant couples and other high-risk populations. The study's results have been recognized by the National Academy of Medicine and the Institute of Medicine, with contributions to the advancement of HIV research and global health initiatives. The study's legacy continues to inform HIV prevention and treatment initiatives, with support from organizations such as the Elizabeth Glaser Pediatric AIDS Foundation and the International AIDS Society.